Bifogade filer
PDF
Kurs
+0,29%
Likviditet
28,6 MSEK
Kalender
| Tid* | ||
| 2025-02-20 | 07:00 | Bokslutskommuniké 2024 |
| 2024-11-11 | - | Kvartalsrapport 2024-Q3 |
| 2024-10-11 | - | 15-6 2024 |
| 2024-09-30 | - | Extra Bolagsstämma 2024 |
| 2024-08-13 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-17 | - | Årsstämma |
| 2024-05-23 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-14 | - | X-dag ordinarie utdelning CALTX 0.00 SEK |
| 2024-05-13 | - | Årsstämma |
| 2024-02-21 | - | Bokslutskommuniké 2023 |
| 2023-11-07 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-17 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-30 | - | Årsstämma |
| 2023-05-25 | - | Årsstämma |
| 2023-05-19 | - | X-dag ordinarie utdelning CALTX 0.00 SEK |
| 2023-05-16 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-23 | - | Bokslutskommuniké 2022 |
| 2022-11-14 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-18 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-20 | - | X-dag ordinarie utdelning CALTX 0.00 SEK |
| 2022-05-19 | - | Årsstämma |
| 2022-05-18 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-24 | - | Bokslutskommuniké 2021 |
| 2021-11-18 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-27 | - | Årsstämma |
| 2021-05-13 | - | Kvartalsrapport 2021-Q1 |
| 2021-05-03 | - | X-dag ordinarie utdelning CALTX 0.00 SEK |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2020-11-12 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-13 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-26 | - | X-dag ordinarie utdelning CALTX 0.00 SEK |
| 2020-06-25 | - | Årsstämma |
| 2020-05-14 | - | Kvartalsrapport 2020-Q1 |
| 2020-03-03 | - | Extra Bolagsstämma 2020 |
| 2020-02-14 | - | Bokslutskommuniké 2019 |
| 2019-11-14 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-15 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-08 | - | Årsstämma |
| 2019-05-08 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-08 | - | X-dag ordinarie utdelning CALTX 0.00 SEK |
| 2019-02-07 | - | Bokslutskommuniké 2018 |
| 2018-11-01 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-16 | - | Kvartalsrapport 2018-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese patients with IgA nephropathy (IgAN).
The clinical trial is a bridging study requiring a limited number of Japanese patients to participate in a study similar in design to that of the global NefIgArd trial. IgA nephropathy is a designated retractable disease in Japan, with an estimated 33,000 patients in Japan* assumed to be suffering from this disease and with limited treatment options for IgAN patients in this country.
Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan - Calliditas Therapeutics AB (https://www.calliditas.se/en/calliditas-therapeutics-announces-license-agreement-with-viatris-to-register-and-commercialize-specialty-therapy-for-iga-nephropathy-in-japan/)
*Japan Intractable Disease Information Center
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com
The information was sent for publication, through the agency of the contact persons set out above, on July 4, 2024 at 08:30 a.m. CET.